QT Vascular and Medtronic Enter Into Asset Purchase Option Agreement for the Chocolate PTA Catheter

 

May 12, 2017—QT Vascular Ltd. announced that it has entered into an asset purchase option agreement with Medtronic for the acquisition of QT Vascular's non–drug-coated Chocolate percutaneous transluminal angioplasty (PTA) catheter. The option is exercisable upon achievement of certain milestones.

In February, QT Vascular announced a definitive agreement with Medtronic for the worldwide distribution of the Chocolate PTA catheter for a period of 5 years and automatically renewable for two additional 1-year periods.

The Chocolate PTA device is approved for use as a stand-alone or adjunctive treatment for stenosis in vessels above and below the knee in Europe, Australia, Turkey, Singapore, Hong Kong, and the United States.

QT Vascular stated that it will continue to focus on achieving milestones related to the Chocolate PTA product line. In addition, the company will continue to develop and market its other products including Chocolate Touch, which is a drug-coated version of Chocolate PTA, and its portfolio of coronary drug and non–drug-coated products. Chocolate Touch has received investigational device exemption approval from the US Food and Drug Administration.

QT Vascular is based in Singapore with a United States subsidiary, TriReme Medical LLC, based in Pleasanton, California.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.